Abstract

BackgroundLung cancer is a leading public health issue worldwide. Although therapeutic approaches have improved drastically in the last decades, the prognosis of lung cancer patients remains suboptimal. The canonical nuclear transcription factor kappa B (NF-κB) signalling pathway is critical in the carcinogenesis of lung cancer. The non-canonical NF-κB signalling pathway (represented by RelB) has attracted increasing attention in the pathogenesis of haematological and epithelial malignancies. However, the function of RelB in non-small cell lung cancer (NSCLC) is still unclear. Recently, high expression of RelB has been detected in NSCLC tissues. We have also demonstrated that RelB expression is an independent prognostic factor in NSCLC patients.MethodsThe mRNA and protein expression of RelB in NSCLC tissues were detected by qRT-PCR and IHC assay. The cell growth of SPC-A1 cells was detected in real-time using the x-Celligence system and xenograft tumour assays. The proliferation capability of cells was detected using a CFSE assay. Cell apoptosis was measured using Annexin V/PI staining, cell cycle was analyzed by the cytometry. Cell migration abilities were detected using the x-Celligence system and wound healing assays. The relative amounts of the active and inactive gelatinases MMP-2 and MMP-9 were examined using gelatin zymography experiments. Apoptosis of RelB depletion SPC-A1 cells after ionizing radiation at 8 Gy. The expression of cellular proliferation signal pathway related-proteins were examined by Western blot analysis.ResultsThe expression of RelB increases in NSCLC tissues. High RelB expression was significantly correlated with advanced-metastatic stage in patients with NSCLC. RelB-silencing inhibits cell growth in vitro and in vivo. We found that RelB affected cell proliferation by regulating AKT phosphorylation. RelB silencing attenuates the migration and invasion abilities of SPC-A1 cells and is likely related to the down regulation of MMP-9 activity and Integrin β-1 expression. In addition, RelB modulated radiation-induced survival of NSCLC cells predominantly by regulating Bcl-xL expression.ConclusionsGiven the involvement of RelB in cell proliferation, migration, invasion, and radio-resistance, RelB functions as an oncogene in NSCLC cells. Our data here shed light on unexplored aspects of RelB in NSCLC.

Highlights

  • Lung cancer is a leading public health issue worldwide

  • The expression of RelB increases in non-small cell lung cancer (NSCLC) tissues The average mRNA levels of the nuclear transcription factor kappa B (NF-κB) subunits in 15 pairs of NSCLC or adjacent non-neoplastic tissues were detected by quantitative real-time PCR (qRT-PCR)

  • We found that RelB silencing affects lung adenocarcinoma SPC-A1 cell proliferation, which can be attributed to inhibited AKT activity

Read more

Summary

Introduction

Lung cancer is a leading public health issue worldwide. The non-canonical NF-κB signalling pathway (represented by RelB) has attracted increasing attention in the pathogenesis of haematological and epithelial malignancies. The function of RelB in non-small cell lung cancer (NSCLC) is still unclear. We have demonstrated that RelB expression is an independent prognostic factor in NSCLC patients. There are two main histological types of lung cancer: small-cell lung carcinoma (SCLC) and non-smallcell lung carcinoma (NSCLC). NSCLC is sub-classified into adenocarcinomas and squamous cell carcinomas. Several driver genes, such as EGFR, c-MET, and the ALK-EML4 fusion gene, have been thoroughly investigated and contribute to aberrant cell proliferation and apoptosis in NSCLC [3]. It remains necessary to discover and understand molecular biomarkers involved in NSCLC progression

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call